For the year ending 2025-12-31, PLYX had $522K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -8,985 |
| Stock-based compensation expense | 4,725 |
| Accounts payable | 398 |
| Due to related party | -39 |
| Accrued expenses related party | 23 |
| Accrued expenses and other current liabilities | -66 |
| Net cash flows used in operating activities | -3,944 |
| Payments related to issuance of common stock | 27 |
| Proceeds from issuance of common stock | 4,493 |
| Net cash flows provided by financing activities | 4,466 |
| Net increase (decrease) in cash and cash equivalents | 522 |
| Cash and cash equivalents, beginning | 4,621 |
| Cash and cash equivalents, ending | 5,143 |
Polaryx Therapeutics, Inc. (PLYX)
Polaryx Therapeutics, Inc. (PLYX)